Improving outcomes for infants exposed to cannabinoids during pregnancy
Official title: Pilot Feasibility Trial of Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure (INTACT)
Run by IDeA States Pediatric Clinical Trials Network · NCT06423664 · Data updated 2026-11-12
This study is trying out a coaching program for parents to see if it helps improve the development of infants who were exposed to cannabinoids before birth.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 7 Days |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | IDeA States Pediatric Clinical Trials Network Research network |
| Locations | 3 sites (Albuquerque, New Mexico and 2 other locations) |
| Status | Recruiting |
| Started | February 6, 2025 |
| Main results expected | June 10, 2026 |
| Study ends | August 31, 2026 |
| Registry record updated | June 24, 2025 |
| Trial ID | NCT06423664 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include birthing parents who used cannabinoids during pregnancy and have a singleton live birth infant who is at least 37 weeks gestation.
✕Probably not a fit
Patients who used other illicit drugs or opiates during pregnancy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The INTACT trial is a multisite pilot feasibility study aimed at evaluating the effectiveness of the INTACT Intervention program in enhancing neurodevelopmental outcomes in infants who were prenatally exposed to cannabinoids. This study will enroll 20 birthing parent/infant dyads across three sites and will focus on the feasibility of the intervention rather than clinical outcomes. The intervention consists of 12 monthly coaching sessions that train birthing parents in effective parenting practices and contingent responding techniques to support their infants' early development. The study will assess participant recruitment, completion, and adherence over a duration of 22 months.
Why it matters
Potential benefit: If successful, this intervention could significantly improve early language, cognitive, and social development in infants exposed to cannabinoids in utero.
How similar studies have gone: While this approach is novel in its specific focus on cannabinoid exposure, similar interventions targeting developmental outcomes in at-risk populations have shown promise in other studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Birthing Parent * Age of majority, as defined by the state of residency * Cannabinoid use during pregnancy confirmed with self-report * Have the ability to speak, read, and understand English * Birthing parent who delivered at one of the hospitals where study team members have clinical privileges to access medical records * Has parental custody of the infant * Singleton pregnancy with live birth * Has an electronic device capable of watching videos and able to stream/download videos for viewing and permitting video conferencing * Has study access to the internet Infant * Term infants at birth (\>37 weeks' gestation) * Biological child of the birthing parent Exclusion Criteria: Birthing Parent * Other illicit drug use, excluding cannabinoids, during pregnancy (such as heroin or cocaine) per self-reported or toxicology results * Opiate use (prescribed or unprescribed) per self-report or toxicology results during this pregnancy * Prolonged hospitalization following delivery longer than 7 days Infant * Has major birth defect(s) including physical anomalies including limb malformations/absence of limbs or chromosomal abnormalities * Diagnosed with neonatal encephalopathy, metabolic disorder, stroke, intracranial hemorrhage, or meningitis during birth hospitalization * Received any major surgical intervention during the birth hospitalization or required a prolonged birth hospitalization (prolonged hospitalization being any hospitalization longer than 7 days)
Where it's running
-
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, United States Recruiting -
Avera Research Institute
Sioux Falls, South Dakota, United States Recruiting -
University of Vermont Medical Center
Burlington, Vermont, United States Recruiting
Study contacts
- Principal investigator: Jessie Maxwell, MD — University of New Mexico
- Study coordinator: Song Ounpraseuth, PhD
- Email: STOunpraseuth@uams.edu
- Phone: (501) 686-5647
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Online self-instructional program for kindergarten and elementary teachers to support autistic children and children with developmental delays
This program tests whether an online, self-guided training helps K–5 public school teachers improve their knowledge, attitudes, and confidence in supporting autistic children and children with developmental delays.
-
Xylitol Gum to Prevent Premature Birth and Protect Baby Health
This trial tests whether chewing xylitol gum during pregnancy reduces preterm birth and improves birth outcomes for pregnant people and their babies.
-
Assessing and intervening on problem behaviors in young children with developmental delays
This study is testing a new way to help young children with developmental delays and their families reduce problem behaviors by using specific assessments and interventions.
-
Assessing motor and cognitive development in infants using wearables
This study is testing a special wearable garment to see how it can help track the motor and cognitive development of infants, both those developing normally and those at risk for developmental issues.
-
Early detection and intervention for preschool children with developmental and behavioral issues
This study tests a new way to help preschool kids with developmental and behavioral challenges by bringing together parents, doctors, and schools to see if it improves kids' behavior and supports families better.
-
Observational study of genetic variants in neurodevelopmental disorders
This study looks at how certain genetic changes affect people with neurodevelopmental disorders like autism and intellectual disabilities to better understand their treatment and related health issues.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.